Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AMYRIS : Amyris's First Commercial Production Facility Complete and Operational

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2011 | 02:05pm CEST

Amyris, Inc., (NASDAQ:AMRS), a renewable chemicals and fuels company, today announced the completion of the first industrial-scale facility for the production of Biofene?, Amyris's renewable farnesene. The production facility is located in Piracicaba, São Paulo, Brazil at a facility owned by Biomin do Brasil Nutri?ão Animal Ltda., a company focusing on animal nutrition. Amyris will operate the production facility and expects to begin Biofene production in May. To produce Biofene, Amyris feeds sugar cane syrup into three dedicated 200,000 liter fermentors containing Amyris proprietary yeast. The yeast digest the syrup feedstock and produce farnesene, which is then separated and purified. Biofene may then be sold directly into industrial applications or put through simple chemical finishing steps to form a broad range of renewable products including squalane, base oil and finished lubricants and diesel.

To achieve production at full industrial scale, Amyris has developed an integrated scale-up process which connects ongoing advances in Amyris research with industrial-scale production. By miniaturizing process conditions found in production-scale fermentors, Amyris has been able to translate yeast performance successfully from discovery to production. Amyris further controls scale-up by testing performance in its pilot plant in Emeryville, Calif., followed by vetting in a second pilot plant and a demonstration facility in Amyris's operations in Campinas, Brazil. Earlier this year, Amyris tested its yeast strains and process in several runs at 100,000 and 200,000 liter scale and generated results that were consistent with previous runs at smaller scale.

"The completion of our first Biofene production facility is a landmark not only for Amyris but also for the renewable products sector," said John Melo, CEO of Amyris. "With this milestone, we are demonstrating that engineered yeast may be used to produce high-value hydrocarbon molecules on a commercial scale. This achievement reinforces our goal of providing No Compromise® renewable alternatives to petroleum to transform the chemicals industry, extend the world's fuel supply and contribute to the betterment of our environment."

Amyris is scaling its production through contract agreements with manufacturers located in Brazil, Europe and the United States, and has five production agreements in place including contract agreements with Antibioticós S.A., Biomin, Paraíso Bioenergia S.A., Tate & Lyle Ingredients Americas, Inc., an affiliate of Tate & Lyle PLC, and a joint venture with Usina São Martinho S.A., one of the largest sugar and ethanol producers in Brazil. Amyris has also established finishing capabilities with Glycotech, Inc.

About Amyris, Inc.

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil S.A., a wholly owned subsidiary, has over 100 employees based in Campinas, Brazil and oversees Amyris's production and commercialization in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC. More information about Amyris is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding commercial-scale production and commercialization and anticipated benefits of our products) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production or commercialization of products, our reliance on third parties to achieve our goals, and other risks detailed in the "Risk Factors" section of Amyris's annual report on Form 10-K filed on March 14, 2011. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

Schwartz Communications
Merrill Freund or Alison Mickey, 415-817-2557
[email protected]


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYRIS INC
04/28 Khang & Khang LLP Announces a Securities Class Action Lawsuit against Amyris,..
04/28 AMYRIS INC : Levi & Korsinsky, LLP Announces an Investigation Concerning Possibl..
04/28 AMYRIS INC : Lundin Law PC Announces a Securities Class Action Lawsuit against A..
04/27 Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Amyris, Inc...
04/27 AMRS LOSS NOTICE : Rosen Law Firm Reminds Amyris, Inc. Investors of the Importan..
04/27 Khang & Khang LLP Announces Securities Class Action Lawsuit against Amyris, I..
04/27 AMYRIS INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against..
04/26 Lundin Law PC Announces Securities Class Action Lawsuit against Amyris, Inc. ..
04/26 AMYRIS INC : Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Acti..
04/25 Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit aga..
More news
Sector news : Industrial Biotechnology Chemicals
04/26 COMPAGNIE DE SAINT GOBAIN : Construction group St Gobain first quarter sales ris..
03/07 Adidas appoints group ecommerce head as new CFO
03/07DJADIDAS EARNINGS : What to Watch
03/02DJGermany's Henkel Offers to Buy GCP's Darex Packaging Tech Unit for $1.05 Bill..
03/02DJHENKEL : Submission Of A Binding Offer For The Darex Packaging Technologies Busi..
More sector news : Industrial Biotechnology Chemicals
News from SeekingAlpha
04/20 INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apollo Global, Pulse Biosciences, Acacia ..
04/18 Amyris deepens relationship with contract manufacturer Blue California with C..
04/18 Amyris cuts $10M off previously announced Q4 and full-year revenue due in dea..
04/12 Amyris - The Correction Is Over
03/02 Amyris' (AMRS) CEO John Melo on Q4 2016 Results - Earnings Call Transcript
Advertisement
Financials ($)
Sales 2017 153 M
EBIT 2017 -41,4 M
Net income 2017 -81,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 1,02x
Capi. / Sales 2018 0,73x
Capitalization 155 M
More Financials
Chart AMYRIS INC
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Full-screen chart
Technical analysis trends AMYRIS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,77 $
Spread / Average Target 411%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John G. Melo President, Chief Executive Officer & Director
Geoffrey M. Duyk Chairman
Kathleen Valiasek Chief Financial Officer
Joel Cherry President-Research & Development
Louis John Doerr Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-25.88%155
HENKEL AG & CO KGAA10.38%54 583
ECOLAB INC.10.13%37 444
SIKA AG30.42%13 717
SYMRISE AG11.14%9 088
TRANSFAR ZHILIAN CO LT..--.--%7 660
More Results